About this trial

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes.

The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to:

1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.

Eligibility criteria

Qualifiers

Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese

Mendelian pattern, especially with early onset (<18 years old)

Syndromic (multiple systems involved)

Lipodystrophic

Disqualifiers

Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes

Refusal of consent for genetic testing

Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)

Women who are currently pregnant

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

13
Colorado
University of Colorado- Denver80045, Aurora United States
Illinois
University of Chicago60637, Chicago United States
Indiana
Indiana University46202, Indianapolis United States
Maryland
University of Maryland21201, Baltimore United States

Sponsors and collaborators

University of South Florida

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator